The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
 
Andreas Rimner
Honoraria - More Health; Research to Practice
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Cybrexa Therapeutics; Merck
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Pfizer (Inst); Varian Medical Systems (Inst)
Travel, Accommodations, Expenses - Philips/Elekta
 
W. Victoria Victoria Lai
Consulting or Advisory Role - AstraZeneca; AstraZeneca; G1 Therapeutics; Jazz Pharmaceuticals; PharmaMar
Research Funding - AbbVie (Inst); Amgen (Inst); BMS (Inst); Daiichi Sankyo (Inst); Merck (Inst)
 
Raffaele Califano
Stock and Other Ownership Interests - The Christie Private Care
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Lilly; MSD; Roche; Takeda
 
Salma K. Jabbour
Consulting or Advisory Role - IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx
Research Funding - Merck Sharp & Dohme (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Corinne Faivre-Finn
No Relationships to Disclose
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus Therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus Therapeutics; Guardant Health; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Oscotec; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Merck Sharp & Dohme; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly; Merck Serono; MSD; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono; Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst)
 
Jinming Yu
No Relationships to Disclose
 
Li Yu
Employment - MSD
 
Bin Zhao
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Maria Catherine Pietanza
Employment - Merck
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Lauren Averett Byers
Consulting or Advisory Role - Abbvie; Alethia Biotherapeutics; AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Genentech; Genmab; Jazz Pharmaceuticals; Merck; Pfizer; PharmaMar; Sierra Oncology
Research Funding - AstraZeneca (Inst); Genmab (Inst); Sierra Oncology; Tolero Pharmaceuticals